Basiliximab

Drugs

Volumn 57, Issue 2, 1999, Pages 207-213

  Onrust, Susan V ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG RECEPTOR BINDING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MICE; RECOMBINANT FUSION PROTEINS;

EID: 0033048519     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00006     Document Type: Article

References (28)

1. Ferguson R. Acute rejection episodes - best predictor of long-term primary cadaveric renal transplant survival. Clin Transpl 1994; 8: 328-31
2. Cole E, Naimark D, Aprile M, et al. An analysis of predictors of long-term cadaveric renal allograft survival. Clin Transpl 1995; 9: 282-8
3. 1/2). Transplantation 1994; 57 (6): 857-9
4. Perico N, Remuzzi G. Prevention of transplant rejection: current treatment guidelines and future developments. Drugs 1997 Oct; 54 (4): 533-70
5. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996 May; 51 (5): 865-94
6. Queen C, Schneider WP, Selick HH, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989 Dec; 86: 10029-33
7. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998 Jan 15; 338 (3): 161-5
8. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997 Dec; 54 (6): 925-75
9. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 Feb; 51 (2): 278-98
10. Janeway Jr CA, Travers P. Immunobiology: the immune system in health and disease. London: Current Biology Ltd and Garland Publishing Inc, 1994
11. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995 Oct 15; 60 (7): 748-56
12. Novartis Pharmaceutical Corporation. Simulect® (basiliximab) monograph. 1998, Novartis Pharmaceutical Corporation (data on file)
13. Kovarik JM, Rawlings E, Sweny O, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996 Apr; 28 (2): 913-4
14. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997 Dec 27; 64: 1701-5
15. Kahan BD, Rajagopalan PR, Hall ML, et al. Basiliximab (Simulect™) is efficacious in reducing the incidence of acute rejection episodes in renal allograft patients: results at 12 months [abstract no. 748]. Transplantation 1998 Jun 27; 65 (12): S189
16. Kovarik J, Mentser M, Broyer P, et al. Disposition of basiliximab, a chimeric IL-2 receptor (CD25) monoclonal antibody, in pediatric renal transplant patients [abstract no. 254]. Transplantation 1998 Jun 27; 65 (12): S66
17. Kovarik JM, Gerbeau C, Legay K, et al. Clinical impact of chimerization on the immunogenicity of T-cell antigen monoclonal antibodies in renal transplantation [abstract no. 253]. Transplantation 1998; 65 Suppl. 1: 142
18. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997 Oct 25; 350: 1193-8
19. Nashan B et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients (published erratum appears in Lancet 1997 Nov; 350 (9089): 1484) Lancet 1997 Oct 25; 350: (1195)
20. Kahan BD, Rajagopalan PR, Hall M, et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation 1998 In press
21. Mulloy LL, Wright F, Hall ML, et al. Basiliximab (Simulect™) reduces acute cellular rejection in renal allografts from cadaveric and living donors [abstract no. 749]. Transplantation 1998 Jun 27; 65 (12): S190
22. Solez K, Axelson RA, Benediktsson H, et al. International standardisation of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-22
23. Nashan B, Thistlethwaite R, Schmidt A-G, et al. Reduced acute rejection and superior one-year renal allograft survival with basiliximab (Simulect™) in patients with diabetics mellitus [abstract no. 707]. Transplantation 1998 Jun 27; 65 (12): S179
24. Lorber M, Evans C, Fastenau J, et al. An economic evaluation of basiliximab (Simulect®) for the prevention of acute rejection in renal allograft recipients [abstract]. Transplantation 1998 Jun 27; 65: S55
25. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of post-transplant lymphoproliferative disorders. Curr Probl Surg 1988 Jun; 25 (6): 367-472
26. Breidenbach T, Kovarik J, Gerbeau C, et al. Pharmacokinetic and pharmacodynamic evaluations of basiliximab (Simulect™) in a phase I/II trial in liver transplanted patients [abstract]. 3rd International Conference on New Trends in Clinical Immunosuppression; 1998 Feb 12-15; Geneva
27. Kovarik J, Breidenbach T, Gerbeau C, et al. Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998 Jul; 64: 66-72
28. Nashan B, Breidenbach T, Korn A, et al. Immunoprophylaxis with a chimeric anti-IL-2R monoclonal antibody in liver transplanted patients [online; abstract]. American Society of Transplant Physicians Meeting, 1997. Available from URL: http://www.astp.org [Accessed 16 Dec 1998]